|
|
||||||||
Genitourinary Imaging |
1 From the Departments of Medical Physics (K.L.Z., A.S.D., S.K., M.M., J.A.K.), Radiology (K.L.Z., S.E., H.H., J.A.K.), Pathology (K.S., V.E.R.), Urology (M.W.K., P.T.S.), Epidemiology and Biostatistics (M.W.K.), and Medicine (J.A.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Received October 28, 2002; revision requested December 12; revision received January 15, 2003; accepted February 28. Supported by National Institutes of Health grants R21 CA 84258-01 and 7-R01 CA76423. Address correspondence to K.L.Z. (e-mail: zakiank@mskcc.org).
PURPOSE: To determine whether cancers of the prostate transition zone (TZ) possess a unique metabolic pattern by which they may be identified at proton magnetic resonance (MR) spectroscopic imaging.
MATERIALS AND METHODS: Findings in 40 patients who underwent combined endorectal MR imaging and hydrogen 1 MR spectroscopic imaging before radical prostatectomy and who had TZ tumor identified subsequently at step-section pathologic analysis were retrospectively reviewed. Within this population, a subset of 16 patients whose TZ tumor had a largest diameter of 1 cm or greater and was included in the MR spectroscopic imaging excitation volume was identified. In these 16 patients, the ratios of choline-containing compounds (Cho) and creatine/phosphocreatine (Cr) to citrate (Cit) (ie, [Cho + Cr]/Cit), Cho/Cr, and Cho/Cit were compared in tumor and control tissues. The presence of only Cho and the absence of all metabolites were also assessed.
RESULTS: The mean values of (Cho + Cr)/Cit, Cho/Cr, and Cho/Cit were different between TZ cancer and control tissues (P = .001, P = .003, and P = .001, respectively; Wilcoxon signed rank test). Nine (56%) of 16 patients had at least one tumor voxel in which Cho comprised the only detectable peak, while no control voxels showed only Cho (P = .008, McNemar test). The percentage of voxels in which no metabolites were detected did not differ between tumor and control tissues (P = .134, McNemar test).
CONCLUSION: TZ cancer has a metabolic profile that is different from that of benign TZ tissue; however, the broad range of metabolite ratios observed in TZ cancer precludes the use of a single ratio to differentiate TZ cancer from benign TZ tissue.
© RSNA, 2003
Index terms: Magnetic resonance (MR), spectroscopy, 844.12145 Magnetic resonance (MR), tissue characterization, 844.12145 Prostate, hyperplasia, 844.316 Prostate, MR, 844.12145 Prostate, neoplasms, 844.32
This article has been cited by other articles:
![]() |
C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P.F. Gade, J. A. Koutcher, W. M. Spees, B. J. Beattie, V. Ponomarev, M. Doubrovin, I. M. Buchanan, T. Beresten, K. L. Zakian, H. C. Le, et al. Imaging Transgene Activity In vivo Cancer Res., April 15, 2008; 68(8): 2878 - 2884. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, Y. Mazaheri, J. Zhang, N. M. Ishill, K. Kuroiwa, and H. Hricak Assessment of Biologic Aggressiveness of Prostate Cancer: Correlation of MR Signal Intensity with Gleason Grade after Radical Prostatectomy Radiology, December 1, 2007; 246(1): 168 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Kundra, P. M. Silverman, S. F. Matin, and H. Choi Imaging in Oncology from The University of Texas M. D. Anderson Cancer Center: Diagnosis, Staging, and Surveillance of Prostate Cancer Am. J. Roentgenol., October 1, 2007; 189(4): 830 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Testa, R. Schiavina, R. Lodi, E. Salizzoni, B. Corti, M. Farsad, J. Kurhanewicz, F. Manferrari, E. Brunocilla, C. Tonon, et al. Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and 11C-Choline PET/CT Radiology, September 1, 2007; 244(3): 797 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hricak, P. L. Choyke, S. C. Eberhardt, S. A. Leibel, and P. T. Scardino Imaging Prostate Cancer: A Multidisciplinary Perspective Radiology, April 1, 2007; 243(1): 28 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Choi, J. K. Kim, N. Kim, K. W. Kim, E. K. Choi, and K.-S. Cho Functional MR Imaging of Prostate Cancer RadioGraphics, January 1, 2007; 27(1): 63 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Futterer, S. W. T. P. J. Heijmink, T. W. J. Scheenen, J. Veltman, H. J. Huisman, P. Vos, C. A. H.-V. de Kaa, J. A. Witjes, P. F. M. Krabbe, A. Heerschap, et al. Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging Radiology, November 1, 2006; 241(2): 449 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wetter, T. A. Engl, D. Nadjmabadi, K. Fliessbach, T. Lehnert, J. Gurung, W.-D. Beecken, and T. J. Vogl Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. Am. J. Roentgenol., September 1, 2006; 187(3): 724 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Akin, E. Sala, C. S. Moskowitz, K. Kuroiwa, N. M. Ishill, D. Pucar, P. T. Scardino, and H. Hricak Transition Zone Prostate Cancers: Features, Detection, Localization, and Staging at Endorectal MR Imaging Radiology, June 1, 2006; 239(3): 784 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, K. Sugimura, Y. Kaji, Y. Kitamura, M. Fujii, I. Hara, and M. Tachibana Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. Am. J. Roentgenol., March 1, 2006; 186(3): 729 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Hricak MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer Br. J. Radiol., October 1, 2005; 78(Special_Issue_2): S103 - S111. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Prando, J. Kurhanewicz, A. P. Borges, E. M. Oliveira Jr, and E. Figueiredo Prostatic Biopsy Directed with Endorectal MR Spectroscopic Imaging Findings in Patients with Elevated Prostate Specific Antigen Levels and Prior Negative Biopsy Findings: Early Experience Radiology, September 1, 2005; 236(3): 903 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pucar, A. Shukla-Dave, H. Hricak, C. S. Moskowitz, K. Kuroiwa, S. Olgac, L. E. Ebora, P. T. Scardino, J. A. Koutcher, and K. L. Zakian Prostate Cancer: Correlation of MR Imaging and MR Spectroscopy with Pathologic Findings after Radiation Therapy-Initial Experience Radiology, August 1, 2005; 236(2): 545 - 553. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Katz-Brull, N. M. Rofsky, M. M. Morrin, I. Pedrosa, D. J. George, M. D. Michaelson, R. P. Marquis, M. Maril, C. Noguera, and R. E. Lenkinski Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy Am J Physiol Renal Physiol, April 1, 2005; 288(4): F637 - F641. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Zakian, K. Sircar, H. Hricak, H.-N. Chen, A. Shukla-Dave, S. Eberhardt, M. Muruganandham, L. Ebora, M. W. Kattan, V. E. Reuter, et al. Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy Radiology, March 1, 2005; 234(3): 804 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Claus, H. Hricak, and R. R. Hattery Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy RadioGraphics, October 1, 2004; 24(suppl_1): S167 - S180. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shukla-Dave, H. Hricak, S. C. Eberhardt, S. Olgac, M. Muruganandham, P. T. Scardino, V. E. Reuter, J. A. Koutcher, and K. L. Zakian Chronic Prostatitis: MR Imaging and 1H MR Spectroscopic Imaging Findings--Initial Observations Radiology, June 1, 2004; 231(3): 717 - 724. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |